All In Biotech

Drug Trial Radar · NCT06979518

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of GSK3862995B Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and European Ancestry

A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of GSK3862995B Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and European Ancestry

Last checked: Nov 19, 2026Latest source record: Jun 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

30

Actual

Start

May 20, 2025

Primary completion

Apr 22, 2026

Study completion Apr 22, 2026

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
May 20, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study aims to assess the ethnic sensitivity of GSK3862995B in terms of safety, tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) in healthy participants of Chinese, Japanese, and European ancestry to enable the inclusion of Chinese and Japanese participants in future global studies.

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

  • GSK3862995BDrug

    GSK3862995B will be administered.

  • PlaceboDrug

    Matching placebo will be administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Adverse Events (AE)Time frame: Up to Week 44 (End of follow up visit)
  2. Number of Participants with Serious Adverse Events (SAE)Time frame: Up to Week 44 (End of follow up visit)
  3. Number of Participants with Clinically Significant Changes in Clinical Laboratory ValuesTime frame: Up to Week 36
  4. Number of Participants with Clinically Significant Changes in Vital SignsTime frame: Up to Week 36
  5. Number of Participants with Clinically Significant Changes in 12-lead (Electrocardiogram (ECG)Time frame: Up to Week 36
  6. Area Under the Serum Concentration-time Curve Extrapolated to Infinity (AUC[0-inf]) of GSK3862995BTime frame: Up to Week 36
  7. Maximum Observed Concentration (Cmax) of GSK3862995BTime frame: Up to Week 36

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Cypress, California

  • GSK Investigational Site

    Las Vegas, Nevada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.